search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Clinical trial on the effect of Azyter in patients with blepharitis.


- candidate number10678
- NTR NumberNTR3192
- ISRCTNISRCTN wordt niet meer aangevraagd.
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR12-dec-2011
- Secondary IDs9/2011 METC
- Public TitleClinical trial on the effect of Azyter in patients with blepharitis.
- Scientific TitleThe effect of azithromicin ophthalmic solution on symptoms, signs, and markers of inflammation in patients with blepharitis.
- ACRONYM
- hypothesisOcular surface inflammation plays a pivotal role in dry eye and possibly in blepharitis. We hypothesize that the quantity of pro-inflammatory cytokines in tears and the expression of markers of inflammation on conjunctival cells are increased in patients with blepharitis. Furthermore, the aim of our project is to evaluate the effect of topical treatment with Azithromycin on symptoms, clinical signs, and ocular surface inflammation induced by blepharitis.
- Healt Condition(s) or Problem(s) studiedBlepharitis
- Inclusion criteria1. Symptoms of blepharitis;
2. HLA-DR > 15% on conjunctival cells;
3. BUT <10 sec;
4. lid margin hyperemia >=2;
5. Meibum quality >= 10.
- Exclusion criteria1. Glaucoma;
2. Ocular surface infections;
3. Corneal ulcer;
4. Conjunctival infections;
5. Treatment with anti-inflammatory drugs and cyclosporine in the 3 months preceding the study;
6. Surgical procedures in the 3 months preceding the study;
7. Antiglaucoma therapies;
8. Contact lens use 7 days before the study.
- mec approval receivedyes
- multicenter trialno
- randomisedyes
- masking/blindingDouble
- controlPlacebo
- groupParallel
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 15-dec-2011
- planned closingdate15-jun-2012
- Target number of participants30
- InterventionsTreatment with Azyter 2 times/day for 3 days and once/day for 3 days will be given at the study group (N=15).

The control group (N=15) includes patients with symptoms and signs of blepharitis as the treated group, but they will undergo the saline solution with the same posology.
- Primary outcomeEvaluation of HLA-DR expression levels after treatment with Azyter.
- Secondary outcomeSymptoms and signs of blepharitis, and level of cytokines in tears after treatment with Azyter.
- Timepoints7 and 21 days.
- Trial web siteN/A
- statusstopped: trial finished
- CONTACT FOR PUBLIC QUERIES Stefano Barabino
- CONTACT for SCIENTIFIC QUERIES Stefano Barabino
- Sponsor/Initiator
- Funding
(Source(s) of Monetary or Material Support)
Thea
- PublicationsOpitz DL, Tyler KF. Efficacy of azithromycin 1% ophthalmic solution for treatment of ocular surface disease from posterior blepharitis. Clin Exp Optom. 2011 Mar;94(2):200-6.
- Brief summaryBlepharitis is a disease of the ocular surface which affects a growing number of patients, and to date there are no definitive treatments available. Inflammation plays a pivotal role in dry eye and possibly in blepharitis. Therefore, we hypothesize that the use of an antibiotic with anti-inflammatory activity may improve symptoms and signs of blepharitis and to reduce the level of ocular surface inflammation mesured as expression of inflammatory cell markers and quantity of inflammatory cytokines in tears.
- Main changes (audit trail)
- RECORD12-dec-2011 - 9-aug-2013


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl